Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Cancer Research UK Phase I Trial of LY3143921 Hydrate (a Cdc7 Inhibitor) Given Orally in Adult Patients With Advanced Solid Tumours

NCT03096054 is registered in ClinicalTrials.gov with Cancer Research UK as lead sponsor.

NCT NCT03096054
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03096054 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Cancer Research UK Phase I Trial of LY3143921 Hydrate (a Cdc7 Inhibitor) Given Orally in Adult Patients With Advanced Solid Tumours
Lead sponsor
Cancer Research UK
Phase
Phase 1
Overall status
Completed
Start date
June 21, 2017
Completion date
April 9, 2025
Enrollment
69 (actual)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer (triple negative type), colorectal cancer, high grade serous ovarian cancer, non small-cell lung cancer (squamous cell variant), pancreatic cancer, squamous carcinoma of the head and neck (human papillomavirus (hpv) negative), urothelial cancer